Drug Discovery & Pharmaceuticals

RSS

MuTaLig: A multi-target paradigm for innovative drug discoveries

Everyone at some point in their life may need to take medication to treat an illness or disease. By finding new and better ways to create drugs, the COST Action Multi-target paradigm for innovative ligand identification in the drug discovery process (MuTaLig) helped improve the effectiveness and safety of the medications, which can ultimately benefit people's health and well-being.

19 Oct 2023

Researchers profile new drug combinations to fight antibiotic-resistant bacteria

Antimicrobial resistance – occurring when pathogens can survive antibiotic treatment – is one of the most rapidly emerging global public health threats today.

19 Oct 2023

Virginia Tech researchers develop new drug design framework to fight COVID-19

As the COVID-19 pandemic scattered and isolated people, researchers across Virginia Tech connected for a data-driven collaboration seeking improved drugs to fight the disease and potentially many other illnesses.

19 Oct 2023

SwRI develops unique technology for safe and efficient synthesis of OPNA oxime antidotes

Southwest Research Institute has developed a unique technology (US20230242487A1) that enables the safe and efficient synthesis of organophosphorus nerve agent (OPNA) oxime antidotes.

17 Oct 2023

Insilico Medicine to present scientific data on novel anti-cancer assets at major cancer conferences

Clinical stage artificial intelligence (AI) drug discovery company Insilico Medicine ("Insilico") has been invited to present scientific data on its novel anti-cancer assets at three major upcoming cancer conferences -- the European Society for Medical Oncology (ESMO) conference in Madrid Oct. 20-24, 2023; the Society of Immunotherapy of Cancer (SITC) conference Nov. 1-5, 2023 in San Diego; and the San Antonio Breast Cancer Symposium (SABCS) Dec. 5-9, 2023.

16 Oct 2023

AstraZeneca announces winners of the 2023 R&D Postdoctoral Challenge

AstraZeneca announced today eight winners of the 2023 R&D Postdoctoral Challenge and agreed to fund their postdoctoral positions at one of the Company’s strategic R&D centres in either Cambridge, UK, Gaithersburg or Boston, US or Gothenburg, Sweden.

14 Oct 2023

BioLizard launches new BioVerse Platform to accelerate life sciences R&D processes

BioLizard, the bioinformatics, data analytics and data management service and consulting company heading digital transformation in the life sciences industry, today announced the launch of its new BioVerse platform.

12 Oct 2023

IU Cancer Center awarded grant to train next generation of cancer drug discovery researchers

The Indiana University Melvin and Bren Simon Comprehensive Cancer Center was awarded a prestigious grant to train the next generation of cancer drug discovery and development researchers.

10 Oct 2023

New method produces highly pure mRNA vaccines with less inflammation risk

A research group from Japan has developed a method to produce highly active mRNA vaccines at high purity using a unique cap to easily separate the desired capped mRNA.

10 Oct 2023

Owlstone Medical recruits first patient in phase 2 clinical trial for the early detection of lung cancer through breath biopsy

Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced recruitment of the first patient into its EVOLUTION Phase 2 clinical trial following successful achievement of key safety and proof of concept milestones in Phase 1.

From Owlstone Medical Ltd 10 Oct 2023

Researchers spearhead a new method to hone in on new cancer drug targets

Searching for new ways to block the growth of cancer cells is like looking for a needle in a haystack. Tumor cells rely on thousands of proteins to function, but only a few of those proteins can be precisely targeted by drugs to treat cancer safely and effectively.

5 Oct 2023

Unlocking the future of cancer care: Overcoming challenges in personalized neoantigen vaccine development

Challenges associated with the development and design of neoantigen cancer vaccines.

5 Oct 2023

Ubiquigent collaborates with Imperial College London on DUB probe discovery to facilitate preclinical and clinical target engagement studies

Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, today announced it is supporting a PhD student in the Institute of Chemical Biology EPSRC Centre for Doctoral Training (CDT) in Chemical Biology, at Imperial College London.

From Ubiquigent Limited 4 Oct 2023

Double-layer polysaccharide hydrogel overcomes challenges of probiotic delivery

In a groundbreaking study, a research team led by Changhu Xue and Xiangzhao Mao from the Ocean University of China has developed a remarkable double-layer polysaccharide hydrogel (DPH) that promises to revolutionize the field of intestine-targeted oral delivery of probiotics.

28 Sep 2023

SRI spins off a biosciences platform that accelerates drug discovery

SRI International announced today it is spinning off Synfini, a biosciences platform that accelerates the process by which pharmaceutical and other companies can design, synthesize, and bring to market molecules for drug development.

26 Sep 2023

Research presents new approach to identify therapeutic targets for human diseases associated with protein phase separation

Recent research demonstrates that protein phase separation (PPS) is widely present in cells and drives a variety of important biological functions.

25 Sep 2023

Machine learning speeds up virtual drug screening by 10-fold

Boosting virtual screening with machine learning allowed for a 10-fold time reduction in the processing of 1.56 billion drug-like molecules. Researchers from the University of Eastern Finland teamed up with industry and supercomputers to carry out one of the world's largest virtual drug screens.

22 Sep 2023

CST and Leica Biosystems partner to enable companion diagnostics for personalized medicine

Cell Signaling Technology (CST), a life science discovery technology company and leading provider of antibodies, kits, and services, is partnered with Leica Biosystems, a technology leader in automated staining and brightfield and fluorescent imaging, to support the development of companion diagnostics (CDx) assays using the extensive portfolio of best-in-class antibodies from CST validated for immunohistochemistry (IHC).

From Cell Signaling Technology 20 Sep 2023

LabGenius & Sanofi partnership yields positive results from AI antibody discovery platform

Today, LabGenius, a pioneer in the use of AI and machine learning for antibody discovery, releases new data from its antibody discovery platform following a multi-year collaboration with Sanofi.

From LabGenius 19 Sep 2023

MGI Partners with National Cancer Centre Singapore to Undergo Comprehensive Genomic Profiling of Asian-Prevalent Cancers

MGI Tech Singapore Pte, Ltd. ("MGI"), a company committed to building core tools and technology to lead life science, recently entered a research partnership with National Cancer Centre Singapore ("NCCS") to facilitate comprehensive, multi-dimensional genomic profiling of Asian-prevalent cancers using MGI's core DNBSEQ™ technology.

From MGI 18 Sep 2023

Drug Discovery & Pharmaceuticals

MuTaLig: A multi-target paradigm for innovative drug discoveries

Researchers profile new drug combinations to fight antibiotic-resistant bacteria

Virginia Tech researchers develop new drug design framework to fight COVID-19

SwRI develops unique technology for safe and efficient synthesis of OPNA oxime antidotes

Insilico Medicine to present scientific data on novel anti-cancer assets at major cancer conferences

AstraZeneca announces winners of the 2023 R&D Postdoctoral Challenge

BioLizard launches new BioVerse Platform to accelerate life sciences R&D processes

IU Cancer Center awarded grant to train next generation of cancer drug discovery researchers

New method produces highly pure mRNA vaccines with less inflammation risk

Owlstone Medical recruits first patient in phase 2 clinical trial for the early detection of lung cancer through breath biopsy

Researchers spearhead a new method to hone in on new cancer drug targets

Unlocking the future of cancer care: Overcoming challenges in personalized neoantigen vaccine development

Ubiquigent collaborates with Imperial College London on DUB probe discovery to facilitate preclinical and clinical target engagement studies

Double-layer polysaccharide hydrogel overcomes challenges of probiotic delivery

SRI spins off a biosciences platform that accelerates drug discovery

Research presents new approach to identify therapeutic targets for human diseases associated with protein phase separation

Machine learning speeds up virtual drug screening by 10-fold

CST and Leica Biosystems partner to enable companion diagnostics for personalized medicine

LabGenius & Sanofi partnership yields positive results from AI antibody discovery platform

MGI Partners with National Cancer Centre Singapore to Undergo Comprehensive Genomic Profiling of Asian-Prevalent Cancers

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News